The cost-effectiveness of prophylaxis with valaciclovir in the management of cytomegalovirus after renal transplantation View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2005-06

AUTHORS

Christophe Legendre, Stephen M. Beard, Anne Crochard, Yvon Lebranchu, Claire Pouteil-Noble, Anke Richter, Isabelle Durand-Zaleski

ABSTRACT

Prophylaxis-based antiviral treatment and intensive monitoring followed by pre-emptive antiviral treatment are both commonly used management strategies to reduce risk of cytomegalovirus (CMV) infection following renal transplantation. This study employed a decision-model approach using published efficacy data and information from a recent survey of French clinical practice to consider the relative costs and outcomes associated with CMV prevention strategies for high-risk patient groups. The cost per case of treating tissue invasive and symptomatic CMV disease was estimated at €15,431 and €10,852, respectively. In the highest infection-risk patient group (positive donor with no previous CMV history) prophylactic oral valaciclovir was shown to avoid the greatest number of CMV disease cases (35 cases per 100 transplanted patients) and reduced the overall CMV-related costs per transplanted patient by around 14% over a ‘wait-and-treat’ baseline strategy. In contrast, intensive monitoring and pre-emptive treatment resulted in a much higher cost per transplanted patient. This analysis suggests that prophylactic treatment remains the most cost-effective approach to the management of CMV in renal-transplanted patients. Further comparative studies between prophylactic and pre-emptive treatment would be a valuable addition to the current evidence based on CMV prevention. More... »

PAGES

172-182

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10198-004-0275-9

DOI

http://dx.doi.org/10.1007/s10198-004-0275-9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1022923673

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/15765243


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Acyclovir", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antiviral Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cost-Benefit Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cytomegalovirus", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cytomegalovirus Infections", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunocompromised Host", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney Transplantation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Valacyclovir", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Valine", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "St. Louis Hospital, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.413328.f", 
          "name": [
            "St. Louis Hospital, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Legendre", 
        "givenName": "Christophe", 
        "id": "sg:person.07562422057.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07562422057.98"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "RTI Health Solutions, Williams House, Manchester Science Park, Lloyd Street North, M15\u00a06SE, Manchester, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "RTI Health Solutions, Manchester, UK", 
            "RTI Health Solutions, Williams House, Manchester Science Park, Lloyd Street North, M15\u00a06SE, Manchester, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Beard", 
        "givenName": "Stephen M.", 
        "id": "sg:person.01237500524.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01237500524.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GlaxoSmithKline, Marly le Roi, France", 
          "id": "http://www.grid.ac/institutes/grid.476503.3", 
          "name": [
            "GlaxoSmithKline, Marly le Roi, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Crochard", 
        "givenName": "Anne", 
        "id": "sg:person.0626017540.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0626017540.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bretonneau Hospital, Tours, France", 
          "id": "http://www.grid.ac/institutes/grid.411777.3", 
          "name": [
            "Bretonneau Hospital, Tours, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lebranchu", 
        "givenName": "Yvon", 
        "id": "sg:person.01075026142.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01075026142.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Lyon-Sud Hospital, Pierre-Benite, France", 
          "id": "http://www.grid.ac/institutes/grid.411430.3", 
          "name": [
            "Lyon-Sud Hospital, Pierre-Benite, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pouteil-Noble", 
        "givenName": "Claire", 
        "id": "sg:person.01217563561.87", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01217563561.87"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "RTI Health Solutions, Research Triangle Park, N.C., USA", 
          "id": "http://www.grid.ac/institutes/grid.416262.5", 
          "name": [
            "RTI Health Solutions, Research Triangle Park, N.C., USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Richter", 
        "givenName": "Anke", 
        "id": "sg:person.0677521431.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0677521431.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "ANAES, St. Denis la Plaine, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "ANAES, St. Denis la Plaine, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Durand-Zaleski", 
        "givenName": "Isabelle", 
        "id": "sg:person.01327533357.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01327533357.46"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.2165/00019053-200321070-00002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008090922", 
          "https://doi.org/10.2165/00019053-200321070-00002"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00019053-200018030-00004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028894956", 
          "https://doi.org/10.2165/00019053-200018030-00004"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2005-06", 
    "datePublishedReg": "2005-06-01", 
    "description": "Prophylaxis-based antiviral treatment and intensive monitoring followed by pre-emptive antiviral treatment are both commonly used management strategies to reduce risk of cytomegalovirus (CMV) infection following renal transplantation. This study employed a decision-model approach using published efficacy data and information from a recent survey of French clinical practice to consider the relative costs and outcomes associated with CMV prevention strategies for high-risk patient groups. The cost per case of treating tissue invasive and symptomatic CMV disease was estimated at \u20ac15,431 and \u20ac10,852, respectively. In the highest infection-risk patient group (positive donor with no previous CMV history) prophylactic oral valaciclovir was shown to avoid the greatest number of CMV disease cases (35 cases per 100 transplanted patients) and reduced the overall CMV-related costs per transplanted patient by around 14% over a \u2018wait-and-treat\u2019 baseline strategy. In contrast, intensive monitoring and pre-emptive treatment resulted in a much higher cost per transplanted patient. This analysis suggests that prophylactic treatment remains the most cost-effective approach to the management of CMV in renal-transplanted patients. Further comparative studies between prophylactic and pre-emptive treatment would be a valuable addition to the current evidence based on CMV prevention.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s10198-004-0275-9", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1297512", 
        "issn": [
          "1439-3972", 
          "1439-6637"
        ], 
        "name": "The European Journal of Health Economics", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "6"
      }
    ], 
    "keywords": [
      "pre-emptive treatment", 
      "renal transplantation", 
      "antiviral treatment", 
      "pre-emptive antiviral treatment", 
      "high-risk patient groups", 
      "CMV prevention strategies", 
      "symptomatic CMV disease", 
      "renal transplanted patients", 
      "management of cytomegalovirus", 
      "management of CMV", 
      "French clinical practice", 
      "intensive monitoring", 
      "CMV disease", 
      "oral valaciclovir", 
      "CMV prevention", 
      "cytomegalovirus infection", 
      "patient group", 
      "prophylactic treatment", 
      "efficacy data", 
      "current evidence", 
      "prevention strategies", 
      "clinical practice", 
      "disease cases", 
      "patients", 
      "further comparative studies", 
      "prophylaxis", 
      "valaciclovir", 
      "treatment", 
      "transplantation", 
      "decision model approach", 
      "valuable addition", 
      "CMV", 
      "cytomegalovirus", 
      "infection", 
      "greater number", 
      "disease", 
      "prevention", 
      "cost-effective approach", 
      "outcomes", 
      "management", 
      "risk", 
      "cases", 
      "tissue", 
      "study", 
      "management strategies", 
      "group", 
      "comparative study", 
      "monitoring", 
      "strategies", 
      "high cost", 
      "evidence", 
      "recent survey", 
      "contrast", 
      "relative costs", 
      "survey", 
      "practice", 
      "data", 
      "addition", 
      "number", 
      "analysis", 
      "cost", 
      "approach", 
      "information", 
      "baseline strategy"
    ], 
    "name": "The cost-effectiveness of prophylaxis with valaciclovir in the management of cytomegalovirus after renal transplantation", 
    "pagination": "172-182", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1022923673"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10198-004-0275-9"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "15765243"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10198-004-0275-9", 
      "https://app.dimensions.ai/details/publication/pub.1022923673"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:33", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_409.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s10198-004-0275-9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10198-004-0275-9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10198-004-0275-9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10198-004-0275-9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10198-004-0275-9'


 

This table displays all metadata directly associated to this object as RDF triples.

233 TRIPLES      21 PREDICATES      102 URIs      92 LITERALS      17 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10198-004-0275-9 schema:about N061ac8a652a94697834627a61fa681ad
2 N305829bbd4374f63b3f520d7f0981927
3 N47b32568473541678606a8b12f020371
4 N77107773660c4dc086173f10b0a43a44
5 N906dcdc617f8469785ce9d7f97e75b22
6 N97b163798bc34f8ba2963b4e2754142c
7 N9946cdad27cd4230912bf5d638267a70
8 Naf7bf0b6286d454a8f501df62fced981
9 Nde67e2cf15784c169f5e339c61a50a2b
10 Nec485283931a4318818130d63658846b
11 anzsrc-for:11
12 anzsrc-for:1103
13 schema:author N695a46645667406a8b95fce633eb733c
14 schema:citation sg:pub.10.2165/00019053-200018030-00004
15 sg:pub.10.2165/00019053-200321070-00002
16 schema:datePublished 2005-06
17 schema:datePublishedReg 2005-06-01
18 schema:description Prophylaxis-based antiviral treatment and intensive monitoring followed by pre-emptive antiviral treatment are both commonly used management strategies to reduce risk of cytomegalovirus (CMV) infection following renal transplantation. This study employed a decision-model approach using published efficacy data and information from a recent survey of French clinical practice to consider the relative costs and outcomes associated with CMV prevention strategies for high-risk patient groups. The cost per case of treating tissue invasive and symptomatic CMV disease was estimated at €15,431 and €10,852, respectively. In the highest infection-risk patient group (positive donor with no previous CMV history) prophylactic oral valaciclovir was shown to avoid the greatest number of CMV disease cases (35 cases per 100 transplanted patients) and reduced the overall CMV-related costs per transplanted patient by around 14% over a ‘wait-and-treat’ baseline strategy. In contrast, intensive monitoring and pre-emptive treatment resulted in a much higher cost per transplanted patient. This analysis suggests that prophylactic treatment remains the most cost-effective approach to the management of CMV in renal-transplanted patients. Further comparative studies between prophylactic and pre-emptive treatment would be a valuable addition to the current evidence based on CMV prevention.
19 schema:genre article
20 schema:isAccessibleForFree false
21 schema:isPartOf N616fc69d61db491e8b38064c805f6837
22 Nc6b004398ccd458face6b2546cf96433
23 sg:journal.1297512
24 schema:keywords CMV
25 CMV disease
26 CMV prevention
27 CMV prevention strategies
28 French clinical practice
29 addition
30 analysis
31 antiviral treatment
32 approach
33 baseline strategy
34 cases
35 clinical practice
36 comparative study
37 contrast
38 cost
39 cost-effective approach
40 current evidence
41 cytomegalovirus
42 cytomegalovirus infection
43 data
44 decision model approach
45 disease
46 disease cases
47 efficacy data
48 evidence
49 further comparative studies
50 greater number
51 group
52 high cost
53 high-risk patient groups
54 infection
55 information
56 intensive monitoring
57 management
58 management of CMV
59 management of cytomegalovirus
60 management strategies
61 monitoring
62 number
63 oral valaciclovir
64 outcomes
65 patient group
66 patients
67 practice
68 pre-emptive antiviral treatment
69 pre-emptive treatment
70 prevention
71 prevention strategies
72 prophylactic treatment
73 prophylaxis
74 recent survey
75 relative costs
76 renal transplantation
77 renal transplanted patients
78 risk
79 strategies
80 study
81 survey
82 symptomatic CMV disease
83 tissue
84 transplantation
85 treatment
86 valaciclovir
87 valuable addition
88 schema:name The cost-effectiveness of prophylaxis with valaciclovir in the management of cytomegalovirus after renal transplantation
89 schema:pagination 172-182
90 schema:productId N61b2d1c182f34c1e858ba20d3a9e71c1
91 N93650c3e61f04a09a71457140d9b7098
92 Nd32f2740b99c4af3a0d77a7e39c868a0
93 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022923673
94 https://doi.org/10.1007/s10198-004-0275-9
95 schema:sdDatePublished 2022-10-01T06:33
96 schema:sdLicense https://scigraph.springernature.com/explorer/license/
97 schema:sdPublisher Nb38585e9e5aa490ba403512558c33fca
98 schema:url https://doi.org/10.1007/s10198-004-0275-9
99 sgo:license sg:explorer/license/
100 sgo:sdDataset articles
101 rdf:type schema:ScholarlyArticle
102 N061ac8a652a94697834627a61fa681ad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Cost-Benefit Analysis
104 rdf:type schema:DefinedTerm
105 N305829bbd4374f63b3f520d7f0981927 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Cytomegalovirus Infections
107 rdf:type schema:DefinedTerm
108 N47b32568473541678606a8b12f020371 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Humans
110 rdf:type schema:DefinedTerm
111 N616fc69d61db491e8b38064c805f6837 schema:volumeNumber 6
112 rdf:type schema:PublicationVolume
113 N61b2d1c182f34c1e858ba20d3a9e71c1 schema:name pubmed_id
114 schema:value 15765243
115 rdf:type schema:PropertyValue
116 N695a46645667406a8b95fce633eb733c rdf:first sg:person.07562422057.98
117 rdf:rest Nbf2097a07e194e62828afdb2ccc1e82e
118 N74657ea51e4a4999a5437eab2771125a rdf:first sg:person.01217563561.87
119 rdf:rest Nb3217bcf2d384b969130743287a6f734
120 N77107773660c4dc086173f10b0a43a44 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Acyclovir
122 rdf:type schema:DefinedTerm
123 N906dcdc617f8469785ce9d7f97e75b22 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Antiviral Agents
125 rdf:type schema:DefinedTerm
126 N93650c3e61f04a09a71457140d9b7098 schema:name doi
127 schema:value 10.1007/s10198-004-0275-9
128 rdf:type schema:PropertyValue
129 N97b163798bc34f8ba2963b4e2754142c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Kidney Transplantation
131 rdf:type schema:DefinedTerm
132 N9946cdad27cd4230912bf5d638267a70 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Valine
134 rdf:type schema:DefinedTerm
135 N9dccaf20a6a24b1ebf22894d9933113d rdf:first sg:person.01075026142.10
136 rdf:rest N74657ea51e4a4999a5437eab2771125a
137 Naf7bf0b6286d454a8f501df62fced981 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Cytomegalovirus
139 rdf:type schema:DefinedTerm
140 Nb3217bcf2d384b969130743287a6f734 rdf:first sg:person.0677521431.14
141 rdf:rest Nc896730f9095442ca7716f20b0720dc7
142 Nb38585e9e5aa490ba403512558c33fca schema:name Springer Nature - SN SciGraph project
143 rdf:type schema:Organization
144 Nbf2097a07e194e62828afdb2ccc1e82e rdf:first sg:person.01237500524.53
145 rdf:rest Nd3972c1f45014816ac69971fa12ad0c5
146 Nc6b004398ccd458face6b2546cf96433 schema:issueNumber 2
147 rdf:type schema:PublicationIssue
148 Nc896730f9095442ca7716f20b0720dc7 rdf:first sg:person.01327533357.46
149 rdf:rest rdf:nil
150 Nd32f2740b99c4af3a0d77a7e39c868a0 schema:name dimensions_id
151 schema:value pub.1022923673
152 rdf:type schema:PropertyValue
153 Nd3972c1f45014816ac69971fa12ad0c5 rdf:first sg:person.0626017540.31
154 rdf:rest N9dccaf20a6a24b1ebf22894d9933113d
155 Nde67e2cf15784c169f5e339c61a50a2b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Immunocompromised Host
157 rdf:type schema:DefinedTerm
158 Nec485283931a4318818130d63658846b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Valacyclovir
160 rdf:type schema:DefinedTerm
161 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
162 schema:name Medical and Health Sciences
163 rdf:type schema:DefinedTerm
164 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
165 schema:name Clinical Sciences
166 rdf:type schema:DefinedTerm
167 sg:journal.1297512 schema:issn 1439-3972
168 1439-6637
169 schema:name The European Journal of Health Economics
170 schema:publisher Springer Nature
171 rdf:type schema:Periodical
172 sg:person.01075026142.10 schema:affiliation grid-institutes:grid.411777.3
173 schema:familyName Lebranchu
174 schema:givenName Yvon
175 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01075026142.10
176 rdf:type schema:Person
177 sg:person.01217563561.87 schema:affiliation grid-institutes:grid.411430.3
178 schema:familyName Pouteil-Noble
179 schema:givenName Claire
180 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01217563561.87
181 rdf:type schema:Person
182 sg:person.01237500524.53 schema:affiliation grid-institutes:None
183 schema:familyName Beard
184 schema:givenName Stephen M.
185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01237500524.53
186 rdf:type schema:Person
187 sg:person.01327533357.46 schema:affiliation grid-institutes:None
188 schema:familyName Durand-Zaleski
189 schema:givenName Isabelle
190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01327533357.46
191 rdf:type schema:Person
192 sg:person.0626017540.31 schema:affiliation grid-institutes:grid.476503.3
193 schema:familyName Crochard
194 schema:givenName Anne
195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0626017540.31
196 rdf:type schema:Person
197 sg:person.0677521431.14 schema:affiliation grid-institutes:grid.416262.5
198 schema:familyName Richter
199 schema:givenName Anke
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0677521431.14
201 rdf:type schema:Person
202 sg:person.07562422057.98 schema:affiliation grid-institutes:grid.413328.f
203 schema:familyName Legendre
204 schema:givenName Christophe
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07562422057.98
206 rdf:type schema:Person
207 sg:pub.10.2165/00019053-200018030-00004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028894956
208 https://doi.org/10.2165/00019053-200018030-00004
209 rdf:type schema:CreativeWork
210 sg:pub.10.2165/00019053-200321070-00002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008090922
211 https://doi.org/10.2165/00019053-200321070-00002
212 rdf:type schema:CreativeWork
213 grid-institutes:None schema:alternateName ANAES, St. Denis la Plaine, France
214 RTI Health Solutions, Williams House, Manchester Science Park, Lloyd Street North, M15 6SE, Manchester, UK
215 schema:name ANAES, St. Denis la Plaine, France
216 RTI Health Solutions, Manchester, UK
217 RTI Health Solutions, Williams House, Manchester Science Park, Lloyd Street North, M15 6SE, Manchester, UK
218 rdf:type schema:Organization
219 grid-institutes:grid.411430.3 schema:alternateName Lyon-Sud Hospital, Pierre-Benite, France
220 schema:name Lyon-Sud Hospital, Pierre-Benite, France
221 rdf:type schema:Organization
222 grid-institutes:grid.411777.3 schema:alternateName Bretonneau Hospital, Tours, France
223 schema:name Bretonneau Hospital, Tours, France
224 rdf:type schema:Organization
225 grid-institutes:grid.413328.f schema:alternateName St. Louis Hospital, Paris, France
226 schema:name St. Louis Hospital, Paris, France
227 rdf:type schema:Organization
228 grid-institutes:grid.416262.5 schema:alternateName RTI Health Solutions, Research Triangle Park, N.C., USA
229 schema:name RTI Health Solutions, Research Triangle Park, N.C., USA
230 rdf:type schema:Organization
231 grid-institutes:grid.476503.3 schema:alternateName GlaxoSmithKline, Marly le Roi, France
232 schema:name GlaxoSmithKline, Marly le Roi, France
233 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...